New Data Bolster Tecentriq Bid To Be First Adjuvant Immunotherapy In NSCLC
US FDA Decision Expected 1 December
Executive Summary
Roche presents further analysis on Tecentriq’s potential first-in-class adjuvant use, which could add up to $3bn a year to revenues.
You may also be interested in...
BMS Gets First Immunotherapy Approval In Neoadjuvant Lung Cancer, Quickly
Opdivo gets approved by the US FDA for neoadjuvant non-small cell lung cancer, an important new early-stage indication for the anti-PD-1 agent that cleared the agency in roughly two months.
Roche’s Polivy Set For Blockbuster Sales After Frontline Lymphoma Success
Roche has not disclosed the full data yet, but is confident that Polivy can surpass CAR-Ts and other competitors to be the new standard of care.
Roche Hopes To Gain Broad Market For Tecentriq In Adjuvant NSCLC
An executive told Scrip the company hopes to target all-comers as well as PD-L1-positive patients.